No Data
No Data
Sinqi Pharmaceutical: Semi-Annual Report 2024
Sinqi Pharmaceutical: 2024 Semi-Annual Report Summary
Shenyang Xingqi Pharmaceutical (300573.SZ): Net income in the first half of the year increased by 92.95% to 0.169 billion yuan and plans to distribute 5 yuan per 10 shares.
Grain Alliance reported its interim report for the first half of 2024 on August 28. During the reporting period, revenue was 0.892 billion yuan, a year-on-year increase of 30.10%; net income attributable to the shareholders of the listed company was 0.169 billion yuan, a year-on-year increase of 92.95%; net income attributable to the shareholders of the listed company excluding non-recurring gains and losses was 0.169 billion yuan, a year-on-year increase of 96.55%; basic earnings per share were 0.97 yuan; proposing a cash dividend of 5 yuan (including tax) per 10 shares to all shareholders.
Shenyang Xingqi PharmaceuticalLtd's (SZSE:300573) Three-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Shenyang Xingqi Pharmaceutical (300573.SZ): All production lines of the company have passed GMP certification.
Shenyang Xingqi Pharmaceutical (300573.SZ) stated on the investor interaction platform on August 16 that all production lines of the company have passed the GMP certification, and the company will arrange production according to the production and operation plan.
Shenyang Xingqi Pharmaceutical (300573.SZ): Low concentration atropine eye drops have reached cooperation with many domestic private chain medical institutions, including Aier Eye Hospital Group.
Shenyang Xingqi Pharmaceutical (300573.SZ) stated on the investor interactive platform on August 16th that the company's low-concentration atropine eye drops have reached cooperation with multiple private chain medical institutions in China, including Aier Eye Hospital Group.
No Data